(Q33951469)

30 July 2017

1 reference

title

Antiviral chemotherapy for the treatment of hepatitis B virus infections (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

Torresi J

1

1 reference

30 July 2017

Locarnini S

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

30 July 2017

1 reference

30 July 2017

118

1 reference

30 July 2017

2 Suppl 1

1 reference

30 July 2017

S83-103

1 reference

Hepatitis B virus. The major etiology of hepatocellular carcinoma

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Persistent infection of humans with hepatitis B virus: mechanisms and consequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatitis B virus replication--an update

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Effect of interferon-gamma on hepatitis B viral antigen expression in primary hepatocyte culture

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Cytotoxic T cell responses in patients with chronic hepatitis B virus infection undergoing HBe antigen/antibody seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

T cell mechanisms in the immunopathogenesis of viral hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Chronic viral hepatitis--benefits of current therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Ribonucleotide reductases

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Physiological concentrations of purines and pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

The role of blood platelets in nucleoside metabolism: regulation of megakaryocyte development and platelet production

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mammalian deoxyribonucleoside kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Nucleoside uptake in rat liver parenchymal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Preclinical aspects of lamivudine and famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

1 reference

7 January 2021

Immunohistochemical analysis of S-phase cells in normal human and rat liver by PC10 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatocyte euploidization is a typical mammalian physiological specialization

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Which DNA polymerases are used for DNA-repair in eukaryotes?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mitochondrial DNA maintenance in vertebrates

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Nuclear control of respiratory chain expression in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Distinct genomic copy number in mitochondria of different mammalian organs.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Respiratory enzymes and mitochondrial morphology of HeLa and L cells treated with chloramphenicol and ethidium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mitochondrial free radical damage and DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Human mitochondria and mitochondrial genome function as a single dynamic cellular unit

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mammalian mitochondrial genetics: heredity, heteroplasmy and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5'-triphospha

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Reasons and limits of substrate activity of modified L-dNTP in DNA biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3'-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Experience with lamivudine against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatitis B reactivation after lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Efficacy of lamivudine re-treatment in a patient with hepatitis B virus (HBV) recurrence after liver transplantation and HBV-DNA breakthrough during the first treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Famciclovir: review of clinical efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Efficiency of oxetanocin-G, a novel nucleoside against the woodchuck hepatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Identification of four conserved motifs among the RNA-dependent polymerase encoding elements

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Therapy for human immunodeficiency virus infection -- what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

Treatment of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970008-4

7 January 2021

10.1016/S0016-5085(00)70008-4

Identifiers

DOI

0 references

1 reference